As of Mar 24
| +0.15 / +12.00%|
The 4 analysts offering 12-month price forecasts for Regulus Therapeutics Inc have a median target of 5.50, with a high estimate of 7.00 and a low estimate of 2.00. The median estimate represents a +292.86% increase from the last price of 1.40.
The current consensus among 7 polled investment analysts is to Hold stock in Regulus Therapeutics Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.